These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 18092247)

  • 1. Hematopoietic cell transplantation: a curative option for sickle cell disease.
    Krishnamurti L
    Pediatr Hematol Oncol; 2007 Dec; 24(8):569-75. PubMed ID: 18092247
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hematopoietic cell transplantation for sickle cell disease: state of the art.
    Krishnamurti L
    Expert Opin Biol Ther; 2007 Feb; 7(2):161-72. PubMed ID: 17250455
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment Options for Sickle Cell Disease.
    Meier ER
    Pediatr Clin North Am; 2018 Jun; 65(3):427-443. PubMed ID: 29803275
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sickle cell anaemia: current therapies.
    Vermylen C
    Transfus Apher Sci; 2013 Oct; 49(2):151-4. PubMed ID: 23954416
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Blood transfusion for preventing primary and secondary stroke in people with sickle cell disease.
    Estcourt LJ; Fortin PM; Hopewell S; Trivella M; Wang WC
    Cochrane Database Syst Rev; 2017 Jan; 1(1):CD003146. PubMed ID: 28094851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evolution of sickle cell disease from a life-threatening disease of children to a chronic disease of adults: The last 40 years.
    Chaturvedi S; DeBaun MR
    Am J Hematol; 2016 Jan; 91(1):5-14. PubMed ID: 26547630
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sickle cell disease.
    McCavit TL
    Pediatr Rev; 2012 May; 33(5):195-204; quiz 205-6. PubMed ID: 22550263
    [No Abstract]   [Full Text] [Related]  

  • 8. The case for and against initiating either hydroxyurea therapy, blood transfusion therapy or hematopoietic stem cell transplant in asymptomatic children with sickle cell disease.
    Kassim AA; DeBaun MR
    Expert Opin Pharmacother; 2014 Feb; 15(3):325-36. PubMed ID: 24392871
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unrelated Umbilical Cord Blood Transplantation for Sickle Cell Disease Following Reduced-Intensity Conditioning: Results of a Phase I Trial.
    Abraham A; Cluster A; Jacobsohn D; Delgado D; Hulbert ML; Kukadiya D; Murray L; Shenoy S
    Biol Blood Marrow Transplant; 2017 Sep; 23(9):1587-1592. PubMed ID: 28578010
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treosulfan-based conditioning regimen for allogeneic haematopoietic stem cell transplantation in children with sickle cell disease.
    Strocchio L; Zecca M; Comoli P; Mina T; Giorgiani G; Giraldi E; Vinti L; Merli P; Regazzi M; Locatelli F
    Br J Haematol; 2015 Jun; 169(5):726-36. PubMed ID: 25818248
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary hypertension in sickle cell disease.
    Hayes MM; Vedamurthy A; George G; Dweik R; Klings ES; Machado RF; Gladwin MT; Wilson KC; Thomson CC;
    Ann Am Thorac Soc; 2014 Nov; 11(9):1488-9. PubMed ID: 25423000
    [No Abstract]   [Full Text] [Related]  

  • 12. Transplantation of a child with sickle cell anemia with an unrelated cord blood unit after reduced intensity conditioning.
    Mazur M; Kurtzberg J; Halperin E; Ciocci G; Szabolcs P
    J Pediatr Hematol Oncol; 2006 Dec; 28(12):840-4. PubMed ID: 17164657
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of donor type and conditioning regimen intensity on allogeneic transplantation outcomes in patients with sickle cell disease: a retrospective multicentre, cohort study.
    Eapen M; Brazauskas R; Walters MC; Bernaudin F; Bo-Subait K; Fitzhugh CD; Hankins JS; Kanter J; Meerpohl JJ; Bolaños-Meade J; Panepinto JA; Rondelli D; Shenoy S; Williamson J; Woolford TL; Gluckman E; Wagner JE; Tisdale JF
    Lancet Haematol; 2019 Nov; 6(11):e585-e596. PubMed ID: 31495699
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prospects for primary stroke prevention in children with sickle cell anaemia.
    Jordan LC; Casella JF; DeBaun MR
    Br J Haematol; 2012 Apr; 157(1):14-25. PubMed ID: 22224940
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Results and current indications of bone marrow allograft in sickle cell disease].
    Bernaudin F
    Pathol Biol (Paris); 1999 Jan; 47(1):59-64. PubMed ID: 10081781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Allogenic hematopoietic stem cell transplantation in sickle cell disease.
    Furstenau DK; Tisdale JF
    Transfus Apher Sci; 2021 Feb; 60(1):103057. PubMed ID: 33485798
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Initiating adjunct low-dose hydroxyurea therapy for stroke prevention in children with SCA during the COVID-19 pandemic.
    DeBaun MR
    Blood; 2020 May; 135(22):1997-1999. PubMed ID: 32282033
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Curative therapies: Allogeneic hematopoietic cell transplantation from matched related donors using myeloablative, reduced intensity, and nonmyeloablative conditioning in sickle cell disease.
    Guilcher GMT; Truong TH; Saraf SL; Joseph JJ; Rondelli D; Hsieh MM
    Semin Hematol; 2018 Apr; 55(2):87-93. PubMed ID: 29958564
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current and emerging treatments for sickle cell disease.
    Monus T; Howell CM
    JAAPA; 2019 Sep; 32(9):1-5. PubMed ID: 31460979
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Principles and indications of chronic transfusion therapy for children with sickle cell disease.
    Ware R
    Clin Adv Hematol Oncol; 2007 Sep; 5(9):686-8. PubMed ID: 17982409
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.